Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Kodiak Sciences Inc. (KOD)

Kodiak Sciences Q2 net loss widens to $65.6 million from $54.3 million

Negative Impact 3 of 5 earnings Written later

Kodiak Sciences reported a second-quarter 2026 net loss of $65.6 million, or $1.05 per share, up from $54.3 million, or $1.03 per share, a year earlier. Research and development spending rose, and cash fell to $125.9 million at June 30, 2026, which the company says will support operations into 2027.

Key points

  • Net loss for the quarter ended June 30, 2026 was $65.6 million, or $1.05 per share, versus $54.3 million, or $1.03 per share, in Q2 2025.
  • R&D expenses rose to $56.1 million from $42.8 million, driven by PEAK/PINNACLE clinical activity and Phase 3 manufacturing.
  • Cash and cash equivalents were $125.9 million at June 30, 2026, down from $209.9 million at December 31, 2025.
  • Topline DAYBREAK Phase 3 data are expected in September 2026 and PEAK Pivotal Analysis 1 data in December 2026.

The filing

CompanyKodiak Sciences Inc. (KOD)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:00 PM ET
Accession number0001193125-26-349107

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.